Privacy Policy

 

What This Privacy Policy Covers

This policy covers how Prestium Pharma, Inc. (“we” or “us”) treats personal information that we collect and receive. Personal information is information about you that is personally identifiable like your name, address, email address, or phone number, and that is not otherwise publicly available. This policy does not apply to the practices of companies that we do not own or control, or to people that we do not employ or manage.

Information Collection and Use

We collect personal information about you when you transmit such information to us, and when you visit certain of our pages. We may combine information about you that we have with information we obtain from business partners or other companies. We may use information for the following general purposes: to customize the content you see, fulfill your requests for services, to respond to a job application or inquiry, improve our services, contact you, conduct research, and provide anonymous reporting for internal and external clients. In connection with a job application or inquiry, you may provide us with information about yourself, such as a resume or job application. We may use this information throughout our organization and its related entities for the purpose of employment consideration, and except when you instruct us otherwise, we will keep such information for future consideration. We automatically receive and record information on our server logs from your browser, including your IP Address and the page you request. We do not currently use cookies, but may determine to do so in the future.

Information Sharing and Disclosure

We do not rent, sell, or share personal information about you with other people except to provide services you’ve requested, when we have your permission, or under the following circumstances: we respond to subpoenas, court orders, or legal process, or to establish or exercise our legal rights or defend against legal claims; we believe it is necessary to share information in order to investigate, prevent, or take action regarding illegal activities; violations of our Terms and Conditions, or as otherwise required by law; and we transfer information about you if we are acquired by or merged with another company.

Confidentiality and Security

We limit access to personal information about you to employees whom we believe reasonably need to have that information to provide services to you or in order to perform their job functions. We are committed to protecting personal information from loss, misuse, disclosure, alteration, unauthorized access and destruction. We take all reasonable precautions to safeguard the confidentiality of personally identifiable information. We limit access to personal information about you to employees whom we believe reasonably need to have that information to provide services to you or in order to perform their job functions.

Changes to this Privacy Policy

We may modify this policy at our sole discretion at any time. We will notify you about significant changes in the way we treat personal information by placing a prominent notice on our site.

 Effective Date: 8.10.2012

 

 

 

 


IMPORTANT SAFETY INFORMATION


Full Prescribing Information


  • OLUX-E® (clobetasol propionate) Foam, 0.05% has been shown to reversibly suppress the hypothalamic-pituitary-adrenal (HPA) axis with the potential for clinical glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid. Evaluate patients periodically for evidence of HPA axis suppression.

  • Cushing's Syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids. Use of OLUX-E Foam for longer than 2 weeks may suppress the immune system.

  • Factors that predispose a patient using a topical corticosteroid to increased total systemic corticosteroid exposure and HPA axis suppression include the use of more potent steroids, use of more than one corticosteroid-containing product at the same time, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure.

  • The pooled incidence of local adverse reactions in trials for atopic dermatitis and psoriasis with OLUX-E Foam was 1.9% for application site atrophy and 1.6% for application site reaction.

  • OLUX-E Foam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

  • Caution should be exercised when OLUX-E Foam is administered to a nursing woman. If used during lactation, OLUX-E Foam should not be applied to the chest to avoid accidental ingestion by the infant.

  • The propellant in this foam is flammable; patients should avoid fire, flame, and/or smoking during and immediately following application.








OLUX-E Foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients aged 12 years and older.

Prestium Prescription
Savings Program